compared EBV-status and innate immune signatures in serum and cerebrospial fluid of untreated relapsing-remitting MS patients and found antibody production against latent EBV antigens mainly in the periphery
Background: Many patients with relapsing-remitting MS (RRMS) show a suboptimal response to first-line disease-modifying drugs. In these patients treatment with natalizumab is highly effective, however
processing speed. Results: Participants' mean age was 45.8 ± 13.3 years and were diagnosed with relapsing-remitting MS (66%), secondary-progressive MS (18%), primary progressive MS (10%), clinically isolated syndrome
efficacy and safety of these drugs was assessed in Mexican patients under treatment for relapsing-remitting multiple sclerosis (RRMS). A parallel, multicenter, prospective and comparative study was carried out. Fifty
aged people. Research and therapies are focused on the early phase of MS, especially relapsing-remitting MS (RRMS). There is the need for novel therapeutic strategies especially oriented towards neuroprotection
volunteers were enrolled in the study. The MS patients were grouped as follows: 35 relapsing-remitting patients with shortdisease- duration (RRMS-SDD) (≤5 years), 23 patients with longer-disease-duration
interferon-1b (INF) and glatiramer acetate (GA) on leptin, resistin, and adiponectin concentrations in relapsing-remitting MS (RRMS) patients. Methods: The study included 154 RRMS patients who were hospitalized
therapeutic agents able to change the natural course of the disorder, particularly of its relapsing-remitting form. More recently, the advances made in understanding the biology of remyelination
reflect the disease status and therefore, would be related to clinical disability. Methods Seven relapsing-remitting MS patients and seven healthy controls underwent perfusion, diffusion and conventional MRI scans. Based
different subtypes of multiple sclerosis (MS). A unifying concept proposes that patients with both relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) have premature thymic involution, which alters peripheral
patterns and demyelinating diseases involving central nervous system, mitochondrial DNA from 13 patients with relapsing-remitting multiple sclerosis, 4 patients with neuromyelitis optica, 1 patient with myelitis, 2…
growth factor may be useful as biomarker for MS evolution. Previous to be declared relapsing-remitting MS (RRMS), MS patients suffer a first attack called clinically isolated syndrome (CIS). Since
stroke and migraine. Methods: We studied patients diagnosed with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), migraine, and ischemic stroke. The number, location and the volume of PVL were
blood will be described. Th ese biomarkers refl ect the presence of relapsing-remitting MS (RRMS) even when the patient is in remission. Moreover, they can diff erentiate patients
surviving past day 7 post- LCMV-infection. Similarly, infection, with H101, of mice with relapsing-remitting experimental autoimmune encephalomyelitis results in elimination of the CD4+ T cell mediated disease…
Tregs inhibited experimental autoimmune encephalomyelitis mediated by functional FoxA1 and PDL1. In patients with relapsing-remitting multiple sclerosis, response to IFN-β-treatment was associated with expansion of…
various clinical trials, resulting in its approval as a fi rst line treatment for relapsing-remitting MS. Th e therapeutic activity of GA has been attributed to immunomodulatory
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.